Summary

Companion Animal Cardiac Drugs Market Summary

The global companion animal cardiac drugs market size was estimated at USD 1.88 billion in 2024 and is projected to reach USD 3.73 billion by 2033, growing at a CAGR of 8.13% from 2025 to 2033. The industry is driven by several key factors, including the rising prevalence of heart-related disorders in pets, increasing pet humanization and expenditure on pet healthcare, and continuous innovation in cardiology treatments.

Advancements in therapies and growing awareness about the importance of cardiac health in animals are encouraging pet owners to pursue specialized care. The rising penetration of pet insurance is playing a crucial role in driving the growth of the companion animal cardiac drugs market. Providers such as Frank and Trusted Insurance Services Ltd offer diverse insurance plans that cover a broad spectrum of illnesses, including heart disease, cancer, arthritis, diabetes, infections, and other chronic conditions. Such coverage eases the financial strain on pet owners, enabling them to opt for advanced treatments and commit to long-term therapies without hesitation. This increased affordability and access encourage earlier veterinary intervention and consistent use of prescribed medications, thereby expanding the treated patient pool and fueling sustained demand for cardiac drugs.

Moreover, the market growth is accelerated by a combination of clinical, pharmaceutical, and awareness-driven initiatives. Collaborations between veterinary schools and private clinics in provinces such as Quebec and Alberta have facilitated the dissemination of updated cardiac care protocols, enabling veterinarians to diagnose and manage heart conditions more effectively. This has expanded the number of companion animals receiving timely treatment, directly increasing the demand for cardiac drugs. In parallel, pharmaceutical firms like Boehringer Ingelheim and Zoetis Canada have strengthened their provincial distribution networks, ensuring consistent availability of advanced medications. Reliable access encourages veterinarians to prescribe therapies with greater confidence, reducing treatment gaps and improving long-term management of chronic cardiac conditions.

At the same time, awareness campaigns led by organizations such as Humane Canada and the Canadian Veterinary Medical Association (CVMA) have played a crucial role in educating pet owners about early warning signs of heart disease, such as persistent coughing or reduced stamina. These initiatives prompt earlier veterinary consultations and timely initiation of treatment, further enlarging the treated patient pool. Collectively, improved clinical protocols, strong drug distribution infrastructure, and greater public awareness are fueling steady market growth, particularly in key drug categories like ACE inhibitors, diuretics, and beta-blockers.

Furthermore, regulatory approval is becoming increasingly important in the veterinary cardiology market as global demand for specialized animal care continues to grow. In the past, slow and restrictive approval processes limited the adoption of innovative treatments and medical devices, but regulatory agencies such as the U.S. FDA, the European Medicines Agency (EMA), and India’s CDSCO have started to adopt more facilitative approaches to ensure faster access to advanced veterinary solutions.

For instance, in May 2024, the FDA approved several animal drugs, including therapies for canine heart failure. Notably, UpCard-CA1, a torsemide oral solution, received conditional approval for treating pulmonary edema in dogs with congestive heart failure caused by myxomatous mitral valve disease (MMVD). Used in combination with established therapies such as pimobendan, spironolactone, and ACE inhibitors, this approval represents a significant advancement in veterinary cardiology by expanding treatment options and improving the management of cardiac conditions in dogs.

Global Companion Animal Cardiac Drugs Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global companion animal cardiac drugs market report based on animal type, product, indication, end-use, distribution channel, and region.

• Animal Type Outlook (Revenue, USD Million, 2021 - 2033)
• Dogs
• Cats
• Horses
• Others
• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Pimobendan
• Spironolactone and benazepril hydrochloride
• Furosemide
• Others
• Indication Outlook (Revenue, USD Million, 2021 - 2033)
• Congestive Heart Failure
• Myocardial (Heart Muscle) Disease
• Arrhythmias
• Others
• End-use Outlook (Revenue, USD Million, 2021 - 2033)
• Veterinary Hospitals & Clinics
• Others
• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
• Hospital/ Clinic Pharmacy
• Retail
• E-Commerce
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
o U.S.
o Canada
o Mexico
• Europe
o UK
o Germany
o France
o Italy
o Spain
o Denmark
o Sweden
o Norway
• Asia Pacific
o Japan
o India
o China
o South Korea
o Australia
o Thailand
• Latin America
o Brazil
o Argentina
• Middle East and Africa (MEA)
o South Africa
o Saudi Arabia
o UAE
o Kuwait
o Qatar
o Oman

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased Database
1.3.2. GVR’s Internal Database
1.3.3. Secondary Sources
1.3.4. Primary Research
1.4. Information/Data Analysis
1.5. Market Formulation & Visualization
1.6. Data Validation & Publishing
1.7. Model Details
1.7.1. Commodity flow analysis
1.7.2. Global Market: CAGR Calculation
1.8. List of Secondary Sources
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Companion animal cardiac drugs market Variable Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market
3.1.2. Ancillary Market
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Rising Prevalence Of Cardiac Diseases In Animals
3.2.1.2. Increasing Animal Health Expenditure
3.2.1.3. Rising Surgical Procedures
3.2.2. Market Restraint Analysis
3.2.2.1. Stringent regulations
3.2.3. Market Opportunity Analysis
3.2.4. Market Challenge Analysis
3.3. Companion animal cardiac drugs market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Bargaining power of suppliers
3.3.1.2. Bargaining power of buyers
3.3.1.3. Threat of substitution
3.3.1.4. Threat of new entrants
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political & Legal landscape
3.3.2.2. Economic and Social landscape
3.3.2.3. Technological landscape
3.3.2.4. Environmental landscape
3.3.3. Regulatory Framework
3.3.4. Pricing Analysis
3.3.5. Estimated Animal Population by key species, key countries, 2024
Chapter 4. Companion animal cardiac drugs Market: Animal Type Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Companion animal cardiac drugs Market: Animal Type Movement Analysis
4.3. Companion animal cardiac drugs market Size & Trend Analysis, by Animal Type, 2021 to 2033 (USD Million)
4.4. Dogs
4.4.1. Dogs Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5. Cats
4.5.1. Cats Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6. Horses
4.6.1. Horses Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.7. Others
4.7.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. Companion Animal Cardiac Drugs Market: Product Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Companion animal cardiac drugs Market: Product Movement Analysis
5.3. Companion animal cardiac drugs market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
5.4. Pimobendan
5.4.1. Pimobendan Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5. spironolactone and benazepril hydrochloride
5.5.1. spironolactone and benazepril hydrochloride Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.6. Furosemide
5.6.1. Furosemide Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.7. Others
5.7.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 6. Companion Animal Cardiac Drugs Market: Indication Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Companion animal cardiac drugs Market: Indication Movement Analysis
6.3. Companion animal cardiac drugs market Size & Trend Analysis, by Indication, 2021 to 2033 (USD Million)
6.4. Congestive Heart Failure
6.4.1. Congestive Heart Failure Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5. Myocardial (Heart Muscle) Disease
6.5.1. Myocardial (Heart Muscle) Disease Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6. Arrhythmias
6.6.1. Arrhythmias Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7. Others
6.7.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. Companion animal cardiac drugs Market: By End Use Estimates & Trend Analysis
7.1. Segment Dashboard
7.2. Companion animal cardiac drugs Market: By End Use Movement Analysis
7.3. Companion animal cardiac drugs market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
7.3.1. Veterinary Hospitals & Clinics
7.3.1.1. Veterinary Hospitals & Clinics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
7.3.2. Others
7.3.2.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 8. Companion animal cardiac drugs Market: By Distribution Channel Estimates & Trend Analysis
8.1. Segment Dashboard
8.2. Companion animal cardiac drugs Market: By Distribution Channel Movement Analysis
8.3. Companion animal cardiac drugs market Size & Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
8.3.1. Hospitals/Clinic pharmacy
8.3.1.1. Hospitals/Clinic pharmacy Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
8.3.2. Retail
8.3.2.1. Retail Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
8.3.3. E-Commerce
8.3.3.1. E-Commerce Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 9. Companion animal cardiac drugs Market: Regional Estimates & Trend Analysis
9.1. Regional Dashboard
9.2. Companion animal cardiac drugs market Share, By Region, 2024 & 2033, USD Million
9.3. Regional Outlook
9.4. North America
9.4.1. North America Companion animal cardiac drugs market Estimates And Forecasts, 2021 - 2033 (USD Million)
9.4.2. U.S.
9.4.2.1. Key Country Dynamics
9.4.2.2. Competitive Scenario
9.4.2.3. U.S. Companion animal cardiac drugs market Estimates And Forecasts, 2021 - 2033 (USD Million)
9.4.3. Canada
9.4.3.1. Key Country Dynamics
9.4.3.2. Competitive Scenario
9.4.3.3. Canada Companion animal cardiac drugs market Estimates And Forecasts, 2021 - 2033 (USD Million)
9.4.4. Mexico
9.4.4.1. Key Country Dynamics
9.4.4.2. Competitive Scenario
9.4.4.3. Mexico Companion animal cardiac drugs market Estimates And Forecasts, 2021 - 2033 (USD Million)
9.5. Europe
9.5.1. Europe Companion animal cardiac drugs market Estimates And Forecasts, 2021 - 2033 (USD Million)
9.5.2. UK
9.5.2.1. Key Country Dynamics
9.5.2.2. Competitive Scenario
9.5.2.3. UK Companion animal cardiac drugs market Estimates And Forecasts, 2021 - 2033 (USD Million)
9.5.3. Germany
9.5.3.1. Key Country Dynamics
9.5.3.2. Competitive Scenario
9.5.3.3. Germany Companion animal cardiac drugs market Estimates And Forecasts, 2021 - 2033 (USD Million)
9.5.4. France
9.5.4.1. Key Country Dynamics
9.5.4.2. Competitive Scenario
9.5.4.3. France Companion animal cardiac drugs market Estimates And Forecasts, 2021 - 2033 (USD Million)
9.5.5. Italy
9.5.5.1. Key Country Dynamics
9.5.5.2. Competitive Scenario
9.5.5.3. Italy Companion animal cardiac drugs market Estimates And Forecasts, 2021 - 2033 (USD Million)
9.5.6. Spain
9.5.6.1. Key Country Dynamics
9.5.6.2. Competitive Scenario
9.5.6.3. Spain Companion animal cardiac drugs market Estimates And Forecasts, 2021 - 2033 (USD Million)
9.5.7. Denmark
9.5.7.1. Key Country Dynamics
9.5.7.2. Competitive Scenario
9.5.7.3. Denmark Companion animal cardiac drugs market Estimates And Forecasts, 2021 - 2033 (USD Million)
9.5.8. Sweden
9.5.8.1. Key Country Dynamics
9.5.8.2. Competitive Scenario
9.5.8.3. Sweden Companion animal cardiac drugs market Estimates And Forecasts, 2021 - 2033 (USD Million)
9.5.9. Norway
9.5.9.1. Key Country Dynamics
9.5.9.2. Competitive Scenario
9.5.9.3. Norway Companion animal cardiac drugs market Estimates And Forecasts, 2021 - 2033 (USD Million)
9.6. Asia Pacific
9.6.1. Asia Pacific Companion animal cardiac drugs market Estimates And Forecasts, 2021 - 2033 (USD Million)
9.6.2. Japan
9.6.2.1. Key Country Dynamics
9.6.2.2. Competitive Scenario
9.6.2.3. Japan Companion animal cardiac drugs market Estimates And Forecasts, 2021 - 2033 (USD Million)
9.6.3. China
9.6.3.1. Key Country Dynamics
9.6.3.2. Competitive Scenario
9.6.3.3. China Companion animal cardiac drugs market Estimates And Forecasts, 2021 - 2033 (USD Million)
9.6.4. India
9.6.4.1. Key Country Dynamics
9.6.4.2. Competitive Scenario
9.6.4.3. India Companion animal cardiac drugs market Estimates And Forecasts, 2021 - 2033 (USD Million)
9.6.5. Australia
9.6.5.1. Key Country Dynamics
9.6.5.2. Competitive Scenario
9.6.5.3. Australia Companion animal cardiac drugs market Estimates And Forecasts, 2021 - 2033 (USD Million)
9.6.6. South Korea
9.6.6.1. Key Country Dynamics
9.6.6.2. Competitive Scenario
9.6.6.3. South Korea Companion animal cardiac drugs market Estimates And Forecasts, 2021 - 2033 (USD Million)
9.6.7. Thailand
9.6.7.1. Key Country Dynamics
9.6.7.2. Competitive Scenario
9.6.7.3. Thailand Companion animal cardiac drugs market Estimates And Forecasts, 2021 - 2033 (USD Million)
9.7. Latin America
9.7.1. Latin America Companion animal cardiac drugs market Estimates And Forecasts, 2021 - 2033 (USD Million)
9.7.2. Brazil
9.7.2.1. Key Country Dynamics
9.7.2.2. Competitive Scenario
9.7.2.3. Brazil Companion animal cardiac drugs market Estimates And Forecasts, 2021 - 2033 (USD Million)
9.7.3. Argentina
9.7.3.1. Key Country Dynamics
9.7.3.2. Competitive Scenario
9.7.3.3. Argentina Companion animal cardiac drugs market Estimates And Forecasts, 2021 - 2033 (USD Million)
9.8. Middle East & Africa
9.8.1. Middle East & Africa Companion animal cardiac drugs market Estimates And Forecasts, 2021 - 2033 (USD Million)
9.8.2. South Africa
9.8.2.1. Key Country Dynamics
9.8.2.2. Competitive Scenario
9.8.2.3. South Africa Companion animal cardiac drugs market Estimates And Forecasts, 2021 - 2033 (USD Million)
9.8.3. Saudi Arabia
9.8.3.1. Key Country Dynamics
9.8.3.2. Competitive Scenario
9.8.3.3. Saudi Arabia Companion animal cardiac drugs market Estimates And Forecasts, 2021 - 2033 (USD Million)
9.8.4. UAE
9.8.4.1. Key Country Dynamics
9.8.4.2. Competitive Scenario
9.8.4.3. UAE Companion animal cardiac drugs market Estimates And Forecasts, 2021 - 2033 (USD Million)
9.8.5. Kuwait
9.8.5.1. Key Country Dynamics
9.8.5.2. Competitive Scenario
9.8.5.3. Kuwait Companion animal cardiac drugs market Estimates And Forecasts, 2021 - 2033 (USD Million)
9.8.6. Qatar
9.8.6.1. Key Country Dynamics
9.8.6.2. Competitive Scenario
9.8.6.3. Kuwait Companion animal cardiac drugs market Estimates And Forecasts, 2021 - 2033 (USD Million)
9.8.7. Oman
9.8.7.1. Key Country Dynamics
9.8.7.2. Competitive Scenario
9.8.7.3. Kuwait Companion animal cardiac drugs market Estimates And Forecasts, 2021 - 2033 (USD Million)
Chapter 10. Competitive Landscape
10.1. Market Participant Categorization
10.2. Company Market Position Analysis/ Heap Map Analysis
10.3. Company Profiles
10.3.1. Boehringer Ingelheim International GmbH
10.3.1.1. Company overview
10.3.1.2. Financial performance
10.3.1.3. Product benchmarking
10.3.1.4. Strategic initiatives
10.3.2. Elanco
10.3.2.1. Company overview
10.3.2.2. Financial performance
10.3.2.3. Product benchmarking
10.3.2.4. Strategic initiatives
10.3.3. Ceva
10.3.3.1. Company overview
10.3.3.2. Financial performance
10.3.3.3. Product benchmarking
10.3.3.4. Strategic initiatives
10.3.4. Merck & Co., Inc.
10.3.4.1. Company overview
10.3.4.2. Financial performance
10.3.4.3. Product benchmarking
10.3.4.4. Strategic initiatives
10.3.5. Virbac
10.3.5.1. Company overview
10.3.5.2. Financial performance
10.3.5.3. Product benchmarking
10.3.5.4. Strategic initiatives
10.3.6. Zoetis
10.3.6.1. Company overview
10.3.6.2. Financial performance
10.3.6.3. Product benchmarking
10.3.6.4. Strategic initiatives
10.3.7. Dechra
10.3.7.1. Company overview
10.3.7.2. Financial performance
10.3.7.3. Product benchmarking
10.3.7.4. Strategic initiatives
10.3.8. Bimeda Corporate
10.3.8.1. Company overview
10.3.8.2. Financial performance
10.3.8.3. Product benchmarking
10.3.8.4. Strategic initiatives
10.3.9. Biogenesis Bago
10.3.9.1. Company overview
10.3.9.2. Financial performance
10.3.9.3. Product benchmarking
10.3.9.4. Strategic initiatives
10.3.10. Vetoquinol SA
10.3.10.1. Company overview
10.3.10.2. Financial performance
10.3.10.3. Product benchmarking
10.3.10.4. Strategic initiatives
10.4. Strategic Initiatives
10.5. List of other Key players